Dutch University Depression Group

This data collection contains the results of post-hoc analyses of the randomized clinical trial Dutch University Depression Group (DUDG) participants (n=122). We aimed to investigate:

a) Whether a treatment-resistant depression genetic risk score (GRS) was associated with nonresponse, nonremission and the number of prior adequate antidepressant trials in patients with a psychotic depression. For this study we created a genetic risk score per participant and used three outcome measures: 1) treatment nonresponse (based on the HAM-D-17 score after 7 weeks of pharmacological treatment), 2) treatment nonremission (based on the HAM-D-17 score after 7 weeks of pharmacological treatment), 3) number of prior adequate antidepressant trials (based on a patients treatment history). We performed correlation and regression analyses and calculated predictive values (area under the curve (AUC), positive prediction values (PPV), negative predictive values (NPV) and odds ratios (OR)). PMID: 38671038.

b) We investigated whether early insomnia improvement (EII) predicted treatment outcome in psychotic depression (PD) and examined if there was an interaction effect between EII and treatment type to assess if findings were treatment-specific. Early insomnia improvement, defined as ≥20% reduced insomnia after 2 weeks, was assessed by the Hamilton Rating Scale for Depression (HAM-D-17). Associations between EII and treatment outcome were examined using logistic regressions. Subsequently, we added interaction terms between EII and treatment type to assess interaction effects. The predictive value of EII was compared with early response on overall depression (≥20% reduced HAM-D-17 score after 2 weeks). PMID: 37930199.

c) We conducted an analysis to examine the prognostic significance of the neutrophil to lymphocyte ratio (NLR) NLR and total white blood cell count (WBC) in pharmacotherapy of PD. Baseline NLR and WBC were examined in their association with response to seven weeks of treatment with antidepressants (venlafaxine or imipramine) and the combination of an antidepressant with an antipsychotic (venlafaxine plus quetiapine) in 87 patients with PD. Logistic regression models were adjusted for age, gender, Body Mass Index (BMI), depression severity, duration of the current episode and number of previous depressive episodes. Secondary outcomes were remission of depression and disappearance of psychotic symptoms. PMID: 34423321.